Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Identifieur interne : 001D77 ( Main/Exploration ); précédent : 001D76; suivant : 001D78Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Auteurs : Josef S. Smolen [Autriche] ; Gerd-Rüdiger Burmester [Allemagne] ; Bernard Combe [France] ; Jeffrey R. Curtis [États-Unis] ; Stephen Hall [Australie] ; Boulos Haraoui [Canada] ; Ronald Van Vollenhoven [Pays-Bas] ; Christopher Cioffi [États-Unis] ; Cécile Ecoffet [Belgique] ; Leon Gervitz [Belgique] ; Lucian Ionescu [Belgique] ; Luke Peterson [États-Unis] ; Roy Fleischmann [États-Unis]Source :
- Lancet (London, England) [ 1474-547X ] ; 2016.
Descripteurs français
- KwdFr :
- Adalimumab (administration et posologie), Adalimumab (usage thérapeutique), Adulte d'âge moyen, Anticorps monoclonaux humanisés (effets indésirables), Antirhumatismaux (administration et posologie), Antirhumatismaux (usage thérapeutique), Certolizumab pégol (administration et posologie), Certolizumab pégol (usage thérapeutique), Femelle, Humains, Mâle, Méthode en double aveugle, Méthode en simple aveugle, Méthotrexate (usage thérapeutique), Polyarthrite rhumatoïde (traitement médicamenteux).
- MESH :
- administration et posologie : Adalimumab, Antirhumatismaux, Certolizumab pégol.
- effets indésirables : Anticorps monoclonaux humanisés.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Adalimumab, Antirhumatismaux, Certolizumab pégol, Méthotrexate.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Méthode en double aveugle, Méthode en simple aveugle.
English descriptors
- KwdEn :
- Adalimumab (administration & dosage), Adalimumab (therapeutic use), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Certolizumab Pegol (administration & dosage), Certolizumab Pegol (therapeutic use), Double-Blind Method, Female, Humans, Male, Methotrexate (therapeutic use), Middle Aged, Single-Blind Method.
- MESH :
- chemical , administration & dosage : Adalimumab, Antirheumatic Agents, Certolizumab Pegol.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Adalimumab, Antirheumatic Agents, Certolizumab Pegol, Methotrexate.
- drug therapy : Arthritis, Rheumatoid.
- Double-Blind Method, Female, Humans, Male, Middle Aged, Single-Blind Method.
Abstract
To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitor at week 12.
DOI: 10.1016/S0140-6736(16)31651-8
PubMed: 27863807
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Canada, France, Pays-Bas, États-Unis
- Alabama, Berlin, Caroline du Nord, Hollande-Septentrionale, Languedoc-Roussillon, Occitanie (région administrative), Région de Bruxelles-Capitale, Texas, Vienne (Autriche)
- Amsterdam, Berlin, Bruxelles, Montpellier, Vienne (Autriche)
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001502
- to stream PubMed, to step Curation: 001480
- to stream PubMed, to step Checkpoint: 001480
- to stream Ncbi, to step Merge: 003F01
- to stream Ncbi, to step Curation: 003F01
- to stream Ncbi, to step Checkpoint: 003F01
- to stream Main, to step Merge: 001D74
- to stream Main, to step Curation: 001D77
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.</title><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name><affiliation wicri:level="3"><nlm:affiliation>Medical University of Vienna and Hietzing Hospital, Vienna, Austria. Electronic address: josef.smolen@wienkav.at.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Medical University of Vienna and Hietzing Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Burmester, Gerd Rudiger" sort="Burmester, Gerd Rudiger" uniqKey="Burmester G" first="Gerd-Rüdiger" last="Burmester">Gerd-Rüdiger Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Charité, University Medicine Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité, University Medicine Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Cabrini Health, Malvern, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Cabrini Health, Malvern, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Haraoui, Boulos" sort="Haraoui, Boulos" uniqKey="Haraoui B" first="Boulos" last="Haraoui">Boulos Haraoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QB</wicri:regionArea><wicri:noRegion>QB</wicri:noRegion></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald" sort="Van Vollenhoven, Ronald" uniqKey="Van Vollenhoven R" first="Ronald" last="Van Vollenhoven">Ronald Van Vollenhoven</name><affiliation wicri:level="3"><nlm:affiliation>Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Cioffi, Christopher" sort="Cioffi, Christopher" uniqKey="Cioffi C" first="Christopher" last="Cioffi">Christopher Cioffi</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Ecoffet, Cecile" sort="Ecoffet, Cecile" uniqKey="Ecoffet C" first="Cécile" last="Ecoffet">Cécile Ecoffet</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Gervitz, Leon" sort="Gervitz, Leon" uniqKey="Gervitz L" first="Leon" last="Gervitz">Leon Gervitz</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Ionescu, Lucian" sort="Ionescu, Lucian" uniqKey="Ionescu L" first="Lucian" last="Ionescu">Lucian Ionescu</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Peterson, Luke" sort="Peterson, Luke" uniqKey="Peterson L" first="Luke" last="Peterson">Luke Peterson</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Fleischmann, Roy" sort="Fleischmann, Roy" uniqKey="Fleischmann R" first="Roy" last="Fleischmann">Roy Fleischmann</name><affiliation wicri:level="2"><nlm:affiliation>Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27863807</idno><idno type="pmid">27863807</idno><idno type="doi">10.1016/S0140-6736(16)31651-8</idno><idno type="wicri:Area/PubMed/Corpus">001502</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001502</idno><idno type="wicri:Area/PubMed/Curation">001480</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001480</idno><idno type="wicri:Area/PubMed/Checkpoint">001480</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001480</idno><idno type="wicri:Area/Ncbi/Merge">003F01</idno><idno type="wicri:Area/Ncbi/Curation">003F01</idno><idno type="wicri:Area/Ncbi/Checkpoint">003F01</idno><idno type="wicri:Area/Main/Merge">001D74</idno><idno type="wicri:Area/Main/Curation">001D77</idno><idno type="wicri:Area/Main/Exploration">001D77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.</title><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name><affiliation wicri:level="3"><nlm:affiliation>Medical University of Vienna and Hietzing Hospital, Vienna, Austria. Electronic address: josef.smolen@wienkav.at.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Medical University of Vienna and Hietzing Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Burmester, Gerd Rudiger" sort="Burmester, Gerd Rudiger" uniqKey="Burmester G" first="Gerd-Rüdiger" last="Burmester">Gerd-Rüdiger Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Charité, University Medicine Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité, University Medicine Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="3"><nlm:affiliation>Montpellier University Hospital, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Montpellier University Hospital, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:affiliation>Monash University, Cabrini Health, Malvern, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University, Cabrini Health, Malvern, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Haraoui, Boulos" sort="Haraoui, Boulos" uniqKey="Haraoui B" first="Boulos" last="Haraoui">Boulos Haraoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QB</wicri:regionArea><wicri:noRegion>QB</wicri:noRegion></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald" sort="Van Vollenhoven, Ronald" uniqKey="Van Vollenhoven R" first="Ronald" last="Van Vollenhoven">Ronald Van Vollenhoven</name><affiliation wicri:level="3"><nlm:affiliation>Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Cioffi, Christopher" sort="Cioffi, Christopher" uniqKey="Cioffi C" first="Christopher" last="Cioffi">Christopher Cioffi</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Ecoffet, Cecile" sort="Ecoffet, Cecile" uniqKey="Ecoffet C" first="Cécile" last="Ecoffet">Cécile Ecoffet</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Gervitz, Leon" sort="Gervitz, Leon" uniqKey="Gervitz L" first="Leon" last="Gervitz">Leon Gervitz</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Ionescu, Lucian" sort="Ionescu, Lucian" uniqKey="Ionescu L" first="Lucian" last="Ionescu">Lucian Ionescu</name><affiliation wicri:level="3"><nlm:affiliation>UCB Pharma, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Peterson, Luke" sort="Peterson, Luke" uniqKey="Peterson L" first="Luke" last="Peterson">Luke Peterson</name><affiliation wicri:level="2"><nlm:affiliation>UCB Pharma, Raleigh, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCB Pharma, Raleigh, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Fleischmann, Roy" sort="Fleischmann, Roy" uniqKey="Fleischmann R" first="Roy" last="Fleischmann">Roy Fleischmann</name><affiliation wicri:level="2"><nlm:affiliation>Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (administration & dosage)</term><term>Adalimumab (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Certolizumab Pegol (administration & dosage)</term><term>Certolizumab Pegol (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Single-Blind Method</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab (administration et posologie)</term><term>Adalimumab (usage thérapeutique)</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Certolizumab pégol (administration et posologie)</term><term>Certolizumab pégol (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Méthode en simple aveugle</term><term>Méthotrexate (usage thérapeutique)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adalimumab</term><term>Antirheumatic Agents</term><term>Certolizumab Pegol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adalimumab</term><term>Antirheumatic Agents</term><term>Certolizumab Pegol</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adalimumab</term><term>Antirhumatismaux</term><term>Certolizumab pégol</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adalimumab</term><term>Antirhumatismaux</term><term>Certolizumab pégol</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Single-Blind Method</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Méthode en simple aveugle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF inhibitors and to assess the efficacy and safety of switching to the other TNF inhibitor without a washout period after insufficient primary response to the first TNF inhibitor at week 12.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Canada</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Alabama</li><li>Berlin</li><li>Caroline du Nord</li><li>Hollande-Septentrionale</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>Région de Bruxelles-Capitale</li><li>Texas</li><li>Vienne (Autriche)</li></region><settlement><li>Amsterdam</li><li>Berlin</li><li>Bruxelles</li><li>Montpellier</li><li>Vienne (Autriche)</li></settlement></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name></region></country><country name="Allemagne"><region name="Berlin"><name sortKey="Burmester, Gerd Rudiger" sort="Burmester, Gerd Rudiger" uniqKey="Burmester G" first="Gerd-Rüdiger" last="Burmester">Gerd-Rüdiger Burmester</name></region></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name></region></country><country name="États-Unis"><region name="Alabama"><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name></region><name sortKey="Cioffi, Christopher" sort="Cioffi, Christopher" uniqKey="Cioffi C" first="Christopher" last="Cioffi">Christopher Cioffi</name><name sortKey="Fleischmann, Roy" sort="Fleischmann, Roy" uniqKey="Fleischmann R" first="Roy" last="Fleischmann">Roy Fleischmann</name><name sortKey="Peterson, Luke" sort="Peterson, Luke" uniqKey="Peterson L" first="Luke" last="Peterson">Luke Peterson</name></country><country name="Australie"><noRegion><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Haraoui, Boulos" sort="Haraoui, Boulos" uniqKey="Haraoui B" first="Boulos" last="Haraoui">Boulos Haraoui</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Van Vollenhoven, Ronald" sort="Van Vollenhoven, Ronald" uniqKey="Van Vollenhoven R" first="Ronald" last="Van Vollenhoven">Ronald Van Vollenhoven</name></region></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Ecoffet, Cecile" sort="Ecoffet, Cecile" uniqKey="Ecoffet C" first="Cécile" last="Ecoffet">Cécile Ecoffet</name></region><name sortKey="Gervitz, Leon" sort="Gervitz, Leon" uniqKey="Gervitz L" first="Leon" last="Gervitz">Leon Gervitz</name><name sortKey="Ionescu, Lucian" sort="Ionescu, Lucian" uniqKey="Ionescu L" first="Lucian" last="Ionescu">Lucian Ionescu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27863807
|texte= Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27863807" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |